TRDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Entrada Therapeutics Inc (TRDA) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the stock has potential upside due to positive analyst sentiment and a promising pipeline, the company's poor financial performance and lack of significant trading signals suggest a cautious approach. It is better to monitor the stock for further developments before making an investment decision.
The stock's technical indicators are mixed. The MACD is negative and expanding, signaling bearish momentum. RSI is neutral at 38.296, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The pre-market price is $12.38, up 3.34%, but it remains below the pivot level of $12.463, indicating resistance ahead.
Positive analyst ratings and price target increases, with a focus on the ENTR-601 series targeting a $1.4Bn Duchenne Muscular Dystrophy market. Analysts believe the stock is undervalued and could see significant upside by 2026.
Additionally, there is no recent news or significant trading activity from insiders, hedge funds, or Congress.
In Q4 2025, revenue dropped to $1.299M (-96.53% YoY), net income fell to -$39.164M (-3562.78% YoY), and EPS declined to -0.94 (-3233.33% YoY). Gross margin remained at 100%, showing no change YoY.
Analysts are bullish on TRDA. Roth Capital raised the price target to $19, Guggenheim initiated coverage with a $20 target, and Oppenheimer set a $21 target. Analysts highlight the company's undervaluation and catalyst-rich 2026, driven by its Duchenne Muscular Dystrophy pipeline and partnerships.
